Prion diseases are neurodegenerative infections with gliosis and vacuolation. The mechanisms of degeneration remain unclear, but chemokines may be important. In current experiments CCR1 knock-out (KO) mice succumbed more rapidly to scrapie infection than WT controls. Infected KO mice had upregulation of CCL3, a CCR1 ligand, and CCR5, a receptor with specificity for CCL3. Both infected KO and WT mice had upregulation of CCR5-mediated signaling involving activation of Erk1/2 in astrocytes; however, activation was earlier in KO mice suggesting a role in pathogenesis. In both mouse strains activation of the Erk1/2 pathway may lead to astrocyte dysfunction resulting in neurodegeneration. Published by Elsevier B.V.
Introduction
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are fatal infectious neurodegenerative disorders that include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in North American deer and elk, and scrapie in sheep. TSEs are characterized by the conversion of normal protease-sensitive prion protein (PrP-sen) to the abnormal partially protease-resistant isoform of prion protein (PrP-res). This process is believed to be the result of an alteration in the normal folding of PrP-sen to create misfolded molecules which form self-aggregates of various sizes (for review, see Caughey and Lansbury, 2003) . Accumulation of aggregated PrP-res in the CNS is associated with pathological changes characteristic of prion diseases including gliosis, vacuolation of the neuropil and neuronal loss (Wells, 1993; Budka et al., 1995) .
The role of PrP-res in the pathogenic process of prion diseases is poorly understood at this time. PrP-res may be able to damage neurons both directly through interactions with PrPsen on the plasma membrane, and indirectly through interactions with glial cells, in particular, microglia and astroglia (Williams et al., 1997; Giese et al., 1998; Betmouni and Perry, 1999; Giese and Kretzschmar, 2001; Eikelenboom et al., 2002; Rock et al., 2004; Wojtera et al., 2005) . Glial activation is a normal response of the brain to many types of damage, and this activity is part of the normal healing process. However, there is also evidence in a variety of diseases that activation of glia might also contribute to the pathological process, perhaps by the release of neurotoxic mediators. For example, in prion diseases, upregulation of several cytokines and chemokines, including tumor necrosis factor-alpha (TNF-α), interleukin 1 alpha (IL-1α), IL-1β, IL-10, IL-13, transforming growth factor beta (TGF-β), CCL5 (RANTES), CXCL9 (MIG), CXCL10 (IP-10) and CXCL13 (B cell-attracting chemokine) have been reported (Campbell et al., 1994; Kordek et al., 1996; Williams et al., 1997; Kim et al., 1999; Baker et al., 2002; Cunningham et al., Journal of Neuroimmunology 196 (2008) 16 -26 www.elsevier.com/locate/jneuroim
